Some cervical cancer patients with advanced or recurrent disease suffer from anaphylaxis after taxane- or platinum-based therapy, and there is no standard treatment for progressive disease that develops during or shortly after platinum-based chemotherapy. Doctors and patients have therefore sought the development of a non-taxane, non-platinum regimen for recurrent cervical cancer.
Platinum-based chemotherapy is considered the standard treatment for advanced or recurrent cervical cancer, and a combination regimen of paclitaxel, platinum, and bevacizumab (Avastin and its FDA-approved biosimilar Mvasi, is widely recognized as the standard treatment. But some cervical cancer patients with advanced or recurrent disease suffer from anaphylaxis after taxane- or platinum-based therapy, and there is no standard treatment for progressive disease that develops during or shortly after platinum-based chemotherapy. Doctors and patients have therefore sought the development of a non-taxane, non-platinum regimen for recurrent cervical cancer.
A recent Japanese case report of 4 women with recurrent cervical cancer, published in Gynecologic Oncology Reports, suggests that bevacizumab with metronomic chemotherapy (treatment in which low doses of anticancer drugs are given on a continuous or frequent, regular schedule such as daily or weekly, usually over a long period of time) of low-dose oral cyclophosphamide (CFA) should be considered for second-line chemotherapy.
The study, by Rose Isono-Nakata, MD, and colleagues, treated 4 patients with recurrent cervical cancer using a regimen of 50 mg of oral CFA daily and 15 mg/kg of bevacizumab (BEV) repeated every 3 weeks (CFA-BEV). The 4 patients followed in the report had no cancer-associated symptoms prior to the initiation of CFA-BEV therapy. The researchers therefore considered metronomic chemotherapy with bevacizumab because it could potentially prolong tumor stabilization with mild toxicity rather than the rapid and short-term regression responses caused by standard MTD therapy.
The researchers report that 1 patient had disease progression after 4 months, but the other 3 continued the regimen until their last follow-up at 13, 14, and 15 months, respectively. One patient suffered from grade 3 neutropenia; however, no grade 2 or higher non-hematological toxicities were observed.
Among the 3 patients who received salvage chemotherapy, 1 had a progression-free survival (PFS) of 4.2 months and the other 2 continued treatment for more than 13 months without disease progression. One patient continued the regimen as maintenance chemotherapy for more than 13 months after radiotherapy for metastases in the pubic region and surrounding soft tissues.
The researchers conclude that CFA-BEV could be a promising potential treatment for patients who experience recurrent disease shortly after platinum treatment, anaphylaxis in response to paclitaxel or platinum, or peripheral neuropathy.
“These cases demonstrate the use of CFA-BEV with minimal toxicity and expected anti-cancer activity and indicate that this regimen should be considered for second-line chemotherapy in advanced recurrent cervical cancer,” they noted. “In addition, the application of this therapy regimen to asymptomatic patients with minor or dormant recurrent disease should be further investigated.”
Reference
Isono-Nakata R, Tsubamoto H, Ueda T, Inoue K, Shibahara H. Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: four cases. Gynecol Oncol Rep. 2018 April 6;24:57-60. doi: 10.1016/j.gore.2018.04.001.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.